This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and ...

In acute myeloid leukemia (AML) that is in complete remission, minimal residual disease (MRD) is presumed to be present, though not morphologically evident. Advances in diagnostics now permit the ...

SAN DIEGO — Allogeneic stem cell transplant is associated with a significant survival benefit in patients with NPM1-mutated acute myeloid leukemia (AML) who are in their first complete remission and ...

KOMET-017-IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential ...

Ten AML patients dosed across 40 mg, 80 mg, and 120 mg TUS with TUS+VEN+AZA triplet SAN DIEGO and TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: ...

Management reiterated plans to initiate two Phase 3 trials under the KOMET-017 protocol for frontline AML in the second half of 2025. The trials will use MRD-negative CR and CR as primary endpoints ...

Mavenclad and Venclexta combination achieved a 96% ORR in newly diagnosed AML and high-risk MDS patients, with high CR rates in MRD-negative individuals. The study reported a 2-year OS rate of 100% ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the full list of presentations by leading researchers ...

SEOUL, South Korea, April 30, 2025 /PRNewswire/ -- Ingenium Therapeutics, a clinical-stage biotechnology company advancing allogeneic natural killer (NK) cell therapies, today announced that it has ...

The presentation "Measurable Residual Disease in AML using Oncomine NGS analysis" by Dr. Jong-Mi Lee from the College of Medicine at The Catholic University of Korea explores the application of ...